{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:48:39Z","timestamp":1784562519900,"version":"3.55.0"},"reference-count":55,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant mesothelioma (MM) is a malignancy arising from the mesothelial cells lining the thoracic and abdominal serosal cavities. The pleural space is the most commonly affected site, accounting for about 80% of cases, while peritoneum makes up the majority of the remaining 20%. The different types of mesotheliomas are generally considered as distinct diseases with specific risk factors, therapeutic strategies and prognoses. Epidemiological and clinical differences between pleural and peritoneal MM raise questions about the involvement of different molecular mechanisms. Since the\n                    <jats:italic>BAP1<\/jats:italic>\n                    gene is involved in the BAP1 cancer syndrome and seems to be a prognostic factor in MM, this review presents an overview of BAP1 alterations in mesothelioma comparing pleural and peritoneal localizations.\n                  <\/jats:p>","DOI":"10.1515\/pp-2016-0007","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T06:02:07Z","timestamp":1464674527000},"page":"91-97","source":"Crossref","is-referenced-by-count":3,"title":["Comparative genetics of diffuse malignant mesothelioma tumors of the peritoneumand pleura, with focus on BAP1 expression"],"prefix":"10.1515","volume":"1","author":[{"given":"Marie","family":"Brevet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"2025120909210684284_j_pp-2016-0007_ref_001_w2aab3b7b2b1b6b1ab1b8b1Aa","doi-asserted-by":"crossref","unstructured":"1. Allen TC, Cagle PT, Churg AM, Colby TV, Gibbs AR, Hammar SP, et al. Localized malignant mesothelioma. Am J Surg Pathol 2005;29:866\u201373.","DOI":"10.1097\/01.pas.0000165529.78945.dc"},{"key":"2025120909210684284_j_pp-2016-0007_ref_002_w2aab3b7b2b1b6b1ab1b8b2Aa","doi-asserted-by":"crossref","unstructured":"2. Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994;51:804\u201311.","DOI":"10.1136\/oem.51.12.804"},{"key":"2025120909210684284_j_pp-2016-0007_ref_003_w2aab3b7b2b1b6b1ab1b8b3Aa","unstructured":"3. Gallot C, Bonnet N, Ch\u00e9ri\u00e9-Challine L. Mandatory notification of mesotheliomas in France: main results, 2012\u20132013 [D\u00e9claration obligatoire des m\u00e9soth\u00e9liomes en France\u202f: principaux r\u00e9sultats, 2012\u20132013). Bull Epid\u00e9miol Hebd 2015;3\u20134:47\u201354."},{"key":"2025120909210684284_j_pp-2016-0007_ref_004_w2aab3b7b2b1b6b1ab1b8b4Aa","unstructured":"4. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, Thymus and heart. Fourth Edition. In IARC; (WHO classification; vol. 7)."},{"key":"2025120909210684284_j_pp-2016-0007_ref_005_w2aab3b7b2b1b6b1ab1b8b5Aa","doi-asserted-by":"crossref","unstructured":"5. Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 2013;34:1413\u201319.","DOI":"10.1093\/carcin\/bgt166"},{"key":"2025120909210684284_j_pp-2016-0007_ref_006_w2aab3b7b2b1b6b1ab1b8b6Aa","doi-asserted-by":"crossref","unstructured":"6. Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, et al. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2011;6:864\u201374.","DOI":"10.1097\/JTO.0b013e318215a07d"},{"key":"2025120909210684284_j_pp-2016-0007_ref_007_w2aab3b7b2b1b6b1ab1b8b7Aa","doi-asserted-by":"crossref","unstructured":"7. Sekido Y. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation. Pathol Int 2011;61:331\u201344.","DOI":"10.1111\/j.1440-1827.2011.02666.x"},{"key":"2025120909210684284_j_pp-2016-0007_ref_008_w2aab3b7b2b1b6b1ab1b8b8Aa","doi-asserted-by":"crossref","unstructured":"8. Zhang X, Tang N, Rishi AK, Pass HI, Wali A. Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options. Methods Mol Biol Clifton NJ 2015;1238:235\u201347.","DOI":"10.1007\/978-1-4939-1804-1_12"},{"key":"2025120909210684284_j_pp-2016-0007_ref_009_w2aab3b7b2b1b6b1ab1b8b9Aa","unstructured":"9. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227\u201331."},{"key":"2025120909210684284_j_pp-2016-0007_ref_010_w2aab3b7b2b1b6b1ab1b8c10Aa","doi-asserted-by":"crossref","unstructured":"10. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21. 1 losses in malignant pleural mesothelioma. Nat Genet 2011;43:668\u201372.","DOI":"10.1038\/ng.855"},{"key":"2025120909210684284_j_pp-2016-0007_ref_011_w2aab3b7b2b1b6b1ab1b8c11Aa","unstructured":"11. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547\u201351."},{"key":"2025120909210684284_j_pp-2016-0007_ref_012_w2aab3b7b2b1b6b1ab1b8c12Aa","doi-asserted-by":"crossref","unstructured":"12. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022\u20135.","DOI":"10.1038\/ng.912"},{"key":"2025120909210684284_j_pp-2016-0007_ref_013_w2aab3b7b2b1b6b1ab1b8c13Aa","doi-asserted-by":"crossref","unstructured":"13. Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, et al. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:e337\u201340.","DOI":"10.1200\/JCO.2011.41.2965"},{"key":"2025120909210684284_j_pp-2016-0007_ref_014_w2aab3b7b2b1b6b1ab1b8c14Aa","unstructured":"14. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993;53:4349\u201355."},{"key":"2025120909210684284_j_pp-2016-0007_ref_015_w2aab3b7b2b1b6b1ab1b8c15Aa","doi-asserted-by":"crossref","unstructured":"15. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 2012;103:868\u201374.","DOI":"10.1111\/j.1349-7006.2012.02223.x"},{"key":"2025120909210684284_j_pp-2016-0007_ref_016_w2aab3b7b2b1b6b1ab1b8c16Aa","doi-asserted-by":"crossref","unstructured":"16. Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2015;10:565\u201376.","DOI":"10.1097\/JTO.0000000000000471"},{"key":"2025120909210684284_j_pp-2016-0007_ref_017_w2aab3b7b2b1b6b1ab1b8c17Aa","doi-asserted-by":"crossref","unstructured":"17. Alakus H, Yost SE, Woo B, French R, Lin GY, Jepsen K, et al. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma. J Transl Med 2015;13:122.","DOI":"10.1186\/s12967-015-0485-1"},{"key":"2025120909210684284_j_pp-2016-0007_ref_018_w2aab3b7b2b1b6b1ab1b8c18Aa","doi-asserted-by":"crossref","unstructured":"18. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol Off J U S Can Acad Pathol Inc 2015;28:1043\u201357.","DOI":"10.1038\/modpathol.2015.65"},{"key":"2025120909210684284_j_pp-2016-0007_ref_019_w2aab3b7b2b1b6b1ab1b8c19Aa","doi-asserted-by":"crossref","unstructured":"19. Taylor S, Carpentieri D, Williams J, Acosta J, Malignant Peritoneal SR. Mesothelioma in an Adolescent Male With BAP1 Deletion. J Pediatr Hematol Oncol 2015;37:e323\u20137.","DOI":"10.1097\/MPH.0000000000000262"},{"key":"2025120909210684284_j_pp-2016-0007_ref_020_w2aab3b7b2b1b6b1ab1b8c20Aa","doi-asserted-by":"crossref","unstructured":"20. Emi M, Yoshikawa Y, Sato C, Sato A, Sato H, Kato T, et al. Frequent genomic rearrangements of BRCA1 associated protein-1 (BAP1) gene in Japanese malignant mesothelioma-characterization of deletions at exon level. J Hum Genet 2015;60:647\u20139.","DOI":"10.1038\/jhg.2015.91"},{"key":"2025120909210684284_j_pp-2016-0007_ref_021_w2aab3b7b2b1b6b1ab1b8c21Aa","doi-asserted-by":"crossref","unstructured":"21. Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J, et al. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 2016;17:228\u201335.","DOI":"10.1080\/15384047.2016.1145850"},{"key":"2025120909210684284_j_pp-2016-0007_ref_022_w2aab3b7b2b1b6b1ab1b8c22Aa","doi-asserted-by":"crossref","unstructured":"22. Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2015;10:492\u20139.","DOI":"10.1097\/JTO.0000000000000436"},{"key":"2025120909210684284_j_pp-2016-0007_ref_023_w2aab3b7b2b1b6b1ab1b8c23Aa","doi-asserted-by":"crossref","unstructured":"23. Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264\u20139.","DOI":"10.1158\/0008-5472.CAN-14-1008"},{"key":"2025120909210684284_j_pp-2016-0007_ref_024_w2aab3b7b2b1b6b1ab1b8c24Aa","doi-asserted-by":"crossref","unstructured":"24. De Rienzo A, Archer MA, Yeap BY, Dao N, Sciaranghella D, Sideris AC, et al. Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res 2016;76:319\u201328.","DOI":"10.1158\/0008-5472.CAN-15-0751"},{"key":"2025120909210684284_j_pp-2016-0007_ref_025_w2aab3b7b2b1b6b1ab1b8c25Aa","doi-asserted-by":"crossref","unstructured":"25. Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 2013;8:1430\u20133.","DOI":"10.1097\/JTO.0b013e31829e7ef9"},{"key":"2025120909210684284_j_pp-2016-0007_ref_026_w2aab3b7b2b1b6b1ab1b8c26Aa","doi-asserted-by":"crossref","unstructured":"26. Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, et al. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PloS One 2015;10:e0119689.","DOI":"10.1371\/journal.pone.0119689"},{"key":"2025120909210684284_j_pp-2016-0007_ref_027_w2aab3b7b2b1b6b1ab1b8c27Aa","doi-asserted-by":"crossref","unstructured":"27. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407\u201316.","DOI":"10.1038\/ng.3520"},{"key":"2025120909210684284_j_pp-2016-0007_ref_028_w2aab3b7b2b1b6b1ab1b8c28Aa","doi-asserted-by":"crossref","unstructured":"28. de la Fouchardi\u00e8re A, Cabaret O, Savin L, Combemale P, Schvartz H, Penet C, et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 2015;88:273\u20137.","DOI":"10.1111\/cge.12472"},{"key":"2025120909210684284_j_pp-2016-0007_ref_029_w2aab3b7b2b1b6b1ab1b8c29Aa","doi-asserted-by":"crossref","unstructured":"29. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer 2013;13:153\u20139.","DOI":"10.1038\/nrc3459"},{"key":"2025120909210684284_j_pp-2016-0007_ref_030_w2aab3b7b2b1b6b1ab1b8c30Aa","doi-asserted-by":"crossref","unstructured":"30. Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d\u2019Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013;92:974\u201380.","DOI":"10.1016\/j.ajhg.2013.04.012"},{"key":"2025120909210684284_j_pp-2016-0007_ref_031_w2aab3b7b2b1b6b1ab1b8c31Aa","doi-asserted-by":"crossref","unstructured":"31. Klebe S, Driml J, Nasu M, Pastorino S, Zangiabadi A, Henderson D, et al. BAP1 hereditary cancer predisposition syndrome: a case report and review of literature. Biomark Res 2015;3:14.","DOI":"10.1186\/s40364-015-0040-5"},{"key":"2025120909210684284_j_pp-2016-0007_ref_032_w2aab3b7b2b1b6b1ab1b8c32Aa","doi-asserted-by":"crossref","unstructured":"32. Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, et al. Germline mutation of BAP1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 2014;74:4388\u201397.","DOI":"10.1158\/0008-5472.CAN-14-1328"},{"key":"2025120909210684284_j_pp-2016-0007_ref_033_w2aab3b7b2b1b6b1ab1b8c33Aa","doi-asserted-by":"crossref","unstructured":"33. Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol 2014;8:37\u201347.","DOI":"10.4137\/CMO.S15239"},{"key":"2025120909210684284_j_pp-2016-0007_ref_034_w2aab3b7b2b1b6b1ab1b8c34Aa","doi-asserted-by":"crossref","unstructured":"34. Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 2015;54:51\u201362.","DOI":"10.1002\/gcc.22218"},{"key":"2025120909210684284_j_pp-2016-0007_ref_035_w2aab3b7b2b1b6b1ab1b8c35Aa","doi-asserted-by":"crossref","unstructured":"35. Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer Amst Neth 2015;87:77\u20139.","DOI":"10.1016\/j.lungcan.2014.10.017"},{"key":"2025120909210684284_j_pp-2016-0007_ref_036_w2aab3b7b2b1b6b1ab1b8c36Aa","doi-asserted-by":"crossref","unstructured":"36. Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, et al. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene 2015;563:103\u20135.","DOI":"10.1016\/j.gene.2015.03.031"},{"key":"2025120909210684284_j_pp-2016-0007_ref_037_w2aab3b7b2b1b6b1ab1b8c37Aa","doi-asserted-by":"crossref","unstructured":"37. Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, et al. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 2016;76:206\u201315.","DOI":"10.1158\/0008-5472.CAN-15-0295"},{"key":"2025120909210684284_j_pp-2016-0007_ref_038_w2aab3b7b2b1b6b1ab1b8c38Aa","doi-asserted-by":"crossref","unstructured":"38. Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, et al. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genet 2015;208:502\u20137.","DOI":"10.1016\/j.cancergen.2015.07.004"},{"key":"2025120909210684284_j_pp-2016-0007_ref_039_w2aab3b7b2b1b6b1ab1b8c39Aa","doi-asserted-by":"crossref","unstructured":"39. Farzin M, Toon CW, Clarkson A, Sioson L, Watson N, Andrici J, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 2015;47:302\u20137.","DOI":"10.1097\/PAT.0000000000000250"},{"key":"2025120909210684284_j_pp-2016-0007_ref_040_w2aab3b7b2b1b6b1ab1b8c40Aa","doi-asserted-by":"crossref","unstructured":"40. Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 2015;39:977\u201382.","DOI":"10.1097\/PAS.0000000000000394"},{"key":"2025120909210684284_j_pp-2016-0007_ref_041_w2aab3b7b2b1b6b1ab1b8c41Aa","doi-asserted-by":"crossref","unstructured":"41. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 2014;20:145\u201351.","DOI":"10.1007\/s12253-013-9677-2"},{"key":"2025120909210684284_j_pp-2016-0007_ref_042_w2aab3b7b2b1b6b1ab1b8c42Aa","doi-asserted-by":"crossref","unstructured":"42. Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol 2016;29:14\u201324.","DOI":"10.1038\/modpathol.2015.121"},{"key":"2025120909210684284_j_pp-2016-0007_ref_043_w2aab3b7b2b1b6b1ab1b8c43Aa","doi-asserted-by":"crossref","unstructured":"43. McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol 2015;46:1670\u20138.","DOI":"10.1016\/j.humpath.2015.06.024"},{"key":"2025120909210684284_j_pp-2016-0007_ref_044_w2aab3b7b2b1b6b1ab1b8c44Aa","doi-asserted-by":"crossref","unstructured":"44. Jaouen A, Thivolet-bejui F, Chalabreysse L, Piaton E, Traverse-glehen A, Isaac S, et\u2009al. BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: a comparative cytological and histological analyses on 50 patients. Ann Pathol 2016;36:111\u201319.","DOI":"10.1016\/j.annpat.2016.01.005"},{"key":"2025120909210684284_j_pp-2016-0007_ref_045_w2aab3b7b2b1b6b1ab1b8c45Aa","doi-asserted-by":"crossref","unstructured":"45. Churg A, Sheffield BS, New G-SF. Markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med 2015;140:318\u201321.","DOI":"10.5858\/arpa.2015-0240-SA"},{"key":"2025120909210684284_j_pp-2016-0007_ref_046_w2aab3b7b2b1b6b1ab1b8c46Aa","doi-asserted-by":"crossref","unstructured":"46. Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 2015;28:1360\u20138.","DOI":"10.1038\/modpathol.2015.87"},{"key":"2025120909210684284_j_pp-2016-0007_ref_047_w2aab3b7b2b1b6b1ab1b8c47Aa","doi-asserted-by":"crossref","unstructured":"47. Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol 2016;40:120\u20136.","DOI":"10.1097\/PAS.0000000000000529"},{"key":"2025120909210684284_j_pp-2016-0007_ref_048_w2aab3b7b2b1b6b1ab1b8c48Aa","doi-asserted-by":"crossref","unstructured":"48. Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015;36:76\u201381.","DOI":"10.1093\/carcin\/bgu227"},{"key":"2025120909210684284_j_pp-2016-0007_ref_049_w2aab3b7b2b1b6b1ab1b8c49Aa","doi-asserted-by":"crossref","unstructured":"49. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol 2011;103:822\u201331.","DOI":"10.1002\/jso.21787"},{"key":"2025120909210684284_j_pp-2016-0007_ref_050_w2aab3b7b2b1b6b1ab1b8c50Aa","doi-asserted-by":"crossref","unstructured":"50. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology 2013;45:651\u20136.","DOI":"10.1097\/PAT.0000000000000002"},{"key":"2025120909210684284_j_pp-2016-0007_ref_051_w2aab3b7b2b1b6b1ab1b8c51Aa","doi-asserted-by":"crossref","unstructured":"51. Tang J, Xi S, Wang G, Wang B, Yan S, Wu Y, et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 2013;30:541.","DOI":"10.1007\/s12032-013-0541-8"},{"key":"2025120909210684284_j_pp-2016-0007_ref_052_w2aab3b7b2b1b6b1ab1b8c52Aa","doi-asserted-by":"crossref","unstructured":"52. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, et al. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 2014;191:603\u201310.","DOI":"10.1016\/j.juro.2013.09.041"},{"key":"2025120909210684284_j_pp-2016-0007_ref_053_w2aab3b7b2b1b6b1ab1b8c53Aa","doi-asserted-by":"crossref","unstructured":"53. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2015;347:1405\u201314.","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2025120909210684284_j_pp-2016-0007_ref_054_w2aab3b7b2b1b6b1ab1b8c54Aa","doi-asserted-by":"crossref","unstructured":"54. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u201342.","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909210684284_j_pp-2016-0007_ref_055_w2aab3b7b2b1b6b1ab1b8c55Aa","doi-asserted-by":"crossref","unstructured":"55. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 2012;19:1416\u201324.","DOI":"10.1245\/s10434-012-2237-2"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/2\/article-p91.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:49:02Z","timestamp":1765277342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1515\/pp-2016-0007"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0007","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5,27]]}}}